Meeting
2017 Genitourinary Cancers Symposium
Indomethacin to inhibit AKR1C3 intracrine androgen production and sensitizes prostate cancer (PCa) to enzalutamide.
Authors
Chong-xian Pan
UC Davis Comprehensive Cancer Center, Sacramento, CA
Chong-xian Pan , Chengfei Liu , Primo Lara Jr., Christopher P. Evans , Marc Dall'Era , Stanley Yap , Wei Lou , Allen Gao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
to be registered
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 161)
DOI
10.1200/JCO.2017.35.6_suppl.161
Abstract #
161
Poster Bd #
F15
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri
Poster
2020 Genitourinary Cancers Symposium
Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes.
First Author: Veronica Pereira Diaz
Poster
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
First Author: Alexandra Sokolova
Poster
2018 Genitourinary Cancers Symposium
Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan